182 related articles for article (PubMed ID: 24145339)
1. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies.
Sudo K; Taketa T; Correa AM; Campagna MC; Wadhwa R; Blum MA; Komaki R; Lee JH; Bhutani MS; Weston B; Skinner HD; Maru DM; Rice DC; Swisher SG; Hofstetter WL; Ajani JA
J Clin Oncol; 2013 Dec; 31(34):4306-10. PubMed ID: 24145339
[TBL] [Abstract][Full Text] [Related]
2. Perineural invasion predicts for locoregional failure in patients with oesophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy.
Patel AK; Pan X; Vila DM; Frankel WL; Chen W; Perry KA; Merritt RE; D'Souza DM; Wuthrick EJ; Williams TM
J Clin Pathol; 2021 Apr; 74(4):228-233. PubMed ID: 32317290
[TBL] [Abstract][Full Text] [Related]
3. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in recurrent esophageal or junctional cancer.
Butter R; Lagarde SM; van Oijen MGH; Anderegg MCJ; Gisbertz SS; Meijer SL; Hulshof MCCM; Bergman JJGHM; van Berge Henegouwen MI; van Laarhoven HWM
Dis Esophagus; 2017 Sep; 30(9):1-9. PubMed ID: 28859371
[TBL] [Abstract][Full Text] [Related]
5. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer.
Shiozaki H; Sudo K; Xiao L; Wadhwa R; Elimova E; Hofstetter WL; Skinner HD; Lee JH; Weston B; Bhutani MS; Blum MA; Maru DM; Ajani JA
Oncology; 2014; 86(5-6):336-9. PubMed ID: 24925190
[TBL] [Abstract][Full Text] [Related]
6. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma.
Gertler R; Siveke JT; Feith M
J Clin Oncol; 2014 Jul; 32(19):2112. PubMed ID: 24868019
[No Abstract] [Full Text] [Related]
7. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
8. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma.
Zhou N; Mitchell KG; Corsini EM; Truong VTT; Antonoff MB; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Ajani JA; Hofstetter WL
Br J Surg; 2021 Oct; 108(10):1207-1215. PubMed ID: 34095952
[TBL] [Abstract][Full Text] [Related]
9. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
[TBL] [Abstract][Full Text] [Related]
10. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation.
Taketa T; Xiao L; Sudo K; Suzuki A; Wadhwa R; Blum MA; Lee JH; Weston B; Bhutani MS; Skinner H; Komaki R; Maru DM; Rice DC; Swisher SG; Hofstetter WL; Ajani JA
Oncology; 2013; 85(2):95-9. PubMed ID: 23860252
[TBL] [Abstract][Full Text] [Related]
11. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al.
Sudo K; Elimova E; Skinner HD; Hofstetter WL; Ajani JA
J Clin Oncol; 2014 Jul; 32(19):2112-3. PubMed ID: 24868018
[No Abstract] [Full Text] [Related]
12. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma.
Marks JL; Hofstetter W; Correa AM; Mehran RJ; Rice D; Roth J; Walsh G; Vaporciyan A; Erasmus J; Chang J; Maru D; Lee JH; Lee J; Ajani JA; Swisher SG
Ann Thorac Surg; 2012 Oct; 94(4):1126-32; discussion 1132-3. PubMed ID: 22921233
[TBL] [Abstract][Full Text] [Related]
13. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy.
Kumagai K; Mariosa D; Tsai JA; Nilsson M; Ye W; Lundell L; Rouvelas I
Dis Esophagus; 2016 Oct; 29(7):734-739. PubMed ID: 26316181
[TBL] [Abstract][Full Text] [Related]
15. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma.
Levinsky NC; Wima K; Morris MC; Ahmad SA; Shah SA; Starnes SL; Van Haren RM;
J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2555-2566. PubMed ID: 31767364
[TBL] [Abstract][Full Text] [Related]
16. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
[TBL] [Abstract][Full Text] [Related]
17. Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.
Yoo C; Park JH; Yoon DH; Park SI; Kim HR; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Kim YH; Kim SB
Ann Thorac Surg; 2012 Dec; 94(6):1862-8. PubMed ID: 22959577
[TBL] [Abstract][Full Text] [Related]
18. Prognostic analysis of salvage esophagectomy after definitive chemoradiotherapy for esophageal squamous cell carcinoma: the importance of lymphadenectomy.
Wang S; Tachimori Y; Hokamura N; Igaki H; Nakazato H; Kishino T
J Thorac Cardiovasc Surg; 2014 Jun; 147(6):1805-11. PubMed ID: 24521950
[TBL] [Abstract][Full Text] [Related]
19. Nomograms for predicting overall and recurrence-free survival after trimodality therapy for esophageal adenocarcinoma.
Merritt RE; Abdel-Rasoul M; Souza DM; Kneuertz PJ
J Surg Oncol; 2021 Mar; 123(4):881-890. PubMed ID: 33333590
[TBL] [Abstract][Full Text] [Related]
20. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.
Taketa T; Correa AM; Suzuki A; Blum MA; Chien P; Lee JH; Welsh J; Lin SH; Maru DM; Erasmus JJ; Bhutani MS; Weston B; Rice DC; Vaporciyan AA; Hofstetter WL; Swisher SG; Ajani JA
Oncology; 2012; 83(5):300-4. PubMed ID: 22964903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
